varitect 5g/1250iu/50 ml %v/v solution for injection
biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection - 5g/1250iu/50 ml %v/v
varitect %v/v solution for injection
biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection - %v/v
subcuvia 160 g/l. solution for injection
baxalta innovations gmbh - human plasma protein >95% immunoglobulins - solution for injection - 160 gram(s)/litre - immunoglobulins, normal human; immunoglobulins, normal human, for extravascular adm. - immune sera and immunoglobulins: immunoglobulins, normal human, for extravascular administration - replacement therapy in adults and children in primary immunodeficiency syndromes such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia - common variable immunodeficiency - severe combined immunodeficiency - igg subclass deficiencies with recurrent infections
octagam 50mg/ml solution for infusion
octapharma (ip) limited - human plasma protein >95% immunoglobulins - solution for infusion - human plasma protein >95% immunoglobulins 50 mg/ml - immune sera and immunoglobulins
megalotect 50 units/ml solution for infusion
biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin cytomegalovirus - solution for infusion - 50 units/ml
gammagard s/dhuman normal immunoglobulin for intravenous administration powder and solvent for solution for infusion
baxalta innovations gmbh - human plasma protein >90% gamma globulin - powder and solvent for solution for infusion - 0.5 g/30 m gram(s)/millilitre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm. - immune sera and immunoglobulins: immunoglobulins, normal human, for intravascular administration - primary immunodeficiency syndromes (pid): congenital agammaglobulinaemia and hypogammaglobulinaemia common variable immunodeficiencies severe combined immunodeficiencies wiskott aldrich syndrome myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections children with congenital aids and recurrent infections
subcuvia 160 g/l solution for injection
baxter healthcare limited - human plasma protein >95% immunoglobulins - solution for injection - 160 g/l
varitect solution for injection
biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection
varitect solution for injection 5g/1250iu/50 ml %v/v
biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection - 5g/1250iu/50 ml %v/v
hepatitis b immunoglobulin-vf 100iu
csl behring (nz) ltd - hepatitis b immunoglobulin, human 160 mg/ml ((>= 98% )as human plasma proteins (exnz)) - solution for injection - 100 iu - active: hepatitis b immunoglobulin, human 160 mg/ml ((>= 98% )as human plasma proteins (exnz)) excipient: glycine water for injection - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.